ANNEXON INC. - COMMON

Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

04 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

03 Jun 2024 15:30:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 May 2024 15:05:00 By Nasdaq GlobeNewswire

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the Bank of America Health Care Conference

09 May 2024 07:00:01 By Nasdaq GlobeNewswire

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

07 May 2024 11:30:00 By Nasdaq GlobeNewswire

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

01 May 2024 07:00:01 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

03 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

26 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

18 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach

21 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

20 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

07 Jan 2024 19:00:05 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

27 Dec 2023 05:30:00 By Nasdaq GlobeNewswire

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

20 Dec 2023 16:27:50 By Nasdaq GlobeNewswire

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

20 Dec 2023 16:10:53 By Nasdaq GlobeNewswire

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

20 Dec 2023 16:08:02 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18 Dec 2023 15:01:00 By Nasdaq GlobeNewswire